Literature DB >> 16985214

Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma.

Adolfo Varona1, Lorena Blanco, José I López, Javier Gil, Ekaitz Agirregoitia, Jon Irazusta, Gorka Larrinaga.   

Abstract

Peptides play important roles in cell regulation and signaling in many tissues and are regulated by peptidases, most of which are highly expressed in the kidney. Several peptide convertases have a function in different tumor stages, and some have been clearly characterized as diagnostic and prognostic markers for solid tumors, including renal cancer; however, little is known about their in vivo role in kidney tumors. The present study compares the activity of a range of peptidases in human tumor samples and nontumor tissue obtained from clear cell renal cell carcinoma (CCRCC) patients. To cover the complete spectrum and subcellular distribution of peptide-converting activity, acid, neutral, basic, and omega activities were selected. CCRCC displays a selective and restricted pattern of peptidase activities. Puromycin-sensitive aminopeptidase activity in the tumor increases [tumor (t) = 10,775 vs. nontumor (n) = 7,635 units of peptidase (UP)/mg protein; P < 0.05], whereas aminopeptidase N decreases (t = 6,664 vs. n = 33,381 UP/mg protein; P < 0.001). Aminopeptidase B activity of the particulate fraction in tumors decreases (t = 2,399 vs. n = 13,536 UP/mg protein; P < 0.001) compared with nontumor tissues, and aspartyl-aminopeptidase activity decreases significantly in CCRCC (t = 137 vs. n = 223 UP/mg protein; P < 0.05). Soluble and particulate pyroglutamyl peptidase I activities, aminopeptidase A activity, and soluble aminopeptidase B activity do not vary in renal cancer. The relative expression for the aforementioned peptidases, assayed using quantitative RT-PCR, increases in CCRCC for aminopeptidases B (1.5-fold) and A (19-fold), aspartyl-aminopeptidase (3.9-fold), puromycin-sensitive aminopeptidase (2.5-fold), and pyroglutamyl peptidase I (7.6-fold). Only aminopeptidase N expression decreases in tumors (1.3-fold). This peptidase activity profile in the neoplastic kidney suggests a specific role for the studied convertases and the possible involvement of an intracrine renin-angiotensin system in the pathogenesis of CCRCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16985214     DOI: 10.1152/ajprenal.00148.2006

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  10 in total

1.  Enzymatic processing of angiotensin peptides by human glomerular endothelial cells.

Authors:  Juan Carlos Q Velez; Jessalyn L Ierardi; Alison M Bland; Thomas A Morinelli; John M Arthur; John R Raymond; Michael G Janech
Journal:  Am J Physiol Renal Physiol       Date:  2012-03-28

2.  Cannabinoid CB₁ receptor is downregulated in clear cell renal cell carcinoma.

Authors:  Gorka Larrinaga; Begoña Sanz; Itxaro Pérez; Lorena Blanco; María L Cándenas; Francisco M Pinto; Javier Gil; José I López
Journal:  J Histochem Cytochem       Date:  2010-09-17       Impact factor: 2.479

3.  Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent.

Authors:  Adolfo Varona; Lorena Blanco; Itxaro Perez; Javier Gil; Jon Irazusta; José I López; M Luz Candenas; Francisco M Pinto; Gorka Larrinaga
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

4.  The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.

Authors:  Malin Wickström; Caroline Haglund; Henrik Lindman; Peter Nygren; Rolf Larsson; Joachim Gullbo
Journal:  Invest New Drugs       Date:  2007-10-06       Impact factor: 3.850

5.  Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon?

Authors:  Olga Golubnitschaja; Kristina Yeghiazaryan; Vincenzo Costigliola; Daniela Trog; Michael Braun; Manuel Debald; Walther Kuhn; Hans H Schild
Journal:  EPMA J       Date:  2013-02-19       Impact factor: 6.543

6.  Altered Activity and Expression of Cytosolic Peptidases in Colorectal Cancer.

Authors:  Itxaro Perez; Lorena Blanco; Begoña Sanz; Peio Errarte; Usue Ariz; Maider Beitia; Ainhoa Fernández; Alberto Loizate; M Luz Candenas; Francisco M Pinto; Javier Gil; José I López; Gorka Larrinaga
Journal:  Int J Med Sci       Date:  2015-06-02       Impact factor: 3.738

7.  Expression and activity of angiotensin-regulating enzymes is associated with prognostic outcome in clear cell renal cell carcinoma patients.

Authors:  Peio Errarte; Maider Beitia; Itxaro Perez; Lorea Manterola; Charles H Lawrie; Jon Danel Solano-Iturri; Julio Calvete-Candenas; Miguel Unda; José I López; Gorka Larrinaga
Journal:  PLoS One       Date:  2017-08-15       Impact factor: 3.240

Review 8.  Aminopeptidase N (CD13) as a target for cancer chemotherapy.

Authors:  Malin Wickström; Rolf Larsson; Peter Nygren; Joachim Gullbo
Journal:  Cancer Sci       Date:  2011-01-30       Impact factor: 6.716

9.  Altered peptidase activities in thyroid neoplasia and hyperplasia.

Authors:  Gorka Larrinaga; Lorena Blanco; Peio Errarte; Maider Beitia; Begoña Sanz; Itxaro Perez; Amaia Irazusta; Clara E Sánchez; Francisco Santaolalla; Leire Andrés; José I López
Journal:  Dis Markers       Date:  2013-11-27       Impact factor: 3.434

10.  Altered glutamyl-aminopeptidase activity and expression in renal neoplasms.

Authors:  Lorena Blanco; Begoña Sanz; Itxaro Perez; Clara E Sánchez; M Luz Cándenas; Francisco M Pinto; Javier Gil; Luis Casis; José I López; Gorka Larrinaga
Journal:  BMC Cancer       Date:  2014-05-30       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.